Editorial: Evolution of Multidrug-Resistant Clinically Important Bacteria and Fungi

Zhu, Ying; Yang, Quan-Yong

doi:10.3389/fmicb.2022.910364

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limitations of microbiome phage therapies remain, however. While bacterial resistance can be reduced by careful selection of therapeutic phage combinations, we know from long experience with small-molecule antibiotics that bacteria can rapidly evolve strategies to overcome even the most carefully designed, mechanistically overlapping therapies [ 107 ]. While few data exist in microbiomes, experience in complex macroscopic ecosystems suggests a real risk of unintended consequences produced by introduction or translocation of predators (the approximate equivalent of lytic phages in microbiomes), and suggest that suppression, rather than eradication, may sustain desired function with fewer long-term risks [ 108 ].…”

Section: Targeted Microbiome Therapeutics: Opportunities and Challengesmentioning

confidence: 99%

A Taxonomy-Agnostic Approach to Targeted Microbiome Therapeutics—Leveraging Principles of Systems Biology

et al. 2023

View full text Add to dashboard Cite

The study of human microbiomes has yielded insights into basic science, and applied therapeutics are emerging. However, conflicting definitions of what microbiomes are and how they affect the health of the “host” are less understood. A major impediment towards systematic design, discovery, and implementation of targeted microbiome therapeutics is the continued reliance on taxonomic indicators to define microbiomes in health and disease. Such reliance often confounds analyses, potentially suggesting associations where there are none, and conversely failing to identify significant, causal relationships. This review article discusses recent discoveries pointing towards a molecular understanding of microbiome “dysbiosis” and away from a purely taxonomic approach. We highlight the growing role of systems biological principles in the complex interrelationships between the gut microbiome and host cells, and review current approaches commonly used in targeted microbiome therapeutics, including fecal microbial transplant, bacteriophage therapies, and the use of metabolic toxins to selectively eliminate specific taxa from dysbiotic microbiomes. These approaches, however, remain wholly or partially dependent on the bacterial taxa involved in dysbiosis, and therefore may not capitalize fully on many therapeutic opportunities presented at the bioactive molecular level. New technologies capable of addressing microbiome-associated diseases as molecular problems, if solved, will open possibilities of new classes and categories of targeted microbiome therapeutics aimed, in principle, at all dysbiosis-driven disorders.

show abstract

Section: Targeted Microbiome Therapeutics: Opportunities and Challengesmentioning

confidence: 99%

A Taxonomy-Agnostic Approach to Targeted Microbiome Therapeutics—Leveraging Principles of Systems Biology

et al. 2023

View full text Add to dashboard Cite

show abstract

Gamma-Rays Empowered the Antimicrobial Potential of TiO2/Fe3O4/MIL-101(Cr) Nanocomposite against Drug-Resistant Bacteria and Pathogenic Fungi

Abd Elkodous,

Abdel-Fatah,

El-Sayyad

2024

J Inorg Organomet Polym

View full text Add to dashboard Cite

The need for smart bimetallic nanoparticles in the battle against pathogenic multi-drug resistant bacteria: a brief communication

El-Sayyad

2024

Discov Bact

View full text Add to dashboard Cite

The expanding threat presented by developing pathogenic multidrug-resistant (MDR) bacteria calls for an urgent need for research, particularly given the growing concern for global public health. Bimetallic nanoparticles (NPs) have the potential to be utilized for a broad variety of pharmacological and biological applications because to their outstanding antibacterial activity at low concentrations and continuous phase stability. This is especially true when it comes to preventing MDR pathogenic bacteria from invading. Several biological synthetic methods for producing bimetallic NPs and the range of analytical methods (used to characterize them) are covered in this brief communication paper. Additionally, I tried to highlight the literature review on the antimicrobial capabilities of several synthesized bimetallic NPs. The final section of this brief communication discussed the structure and mechanism of action of the synthesized bimetallic NPs against pathogenic bacteria. Electrostatic interaction, damage to cell membranes, change of enzymes and proteins, oxidative stress and the production of reactive oxygen species (ROS), binding to proteins that disturbs the electron transport chain and disturbs homeostasis, signal transduction suppression, and genotoxicity are some possible associations with the phenomenon being studied.

show abstract

Editorial: Evolution of Multidrug-Resistant Clinically Important Bacteria and Fungi

Cited by 3 publications

References 4 publications

A Taxonomy-Agnostic Approach to Targeted Microbiome Therapeutics—Leveraging Principles of Systems Biology

A Taxonomy-Agnostic Approach to Targeted Microbiome Therapeutics—Leveraging Principles of Systems Biology

Gamma-Rays Empowered the Antimicrobial Potential of TiO2/Fe3O4/MIL-101(Cr) Nanocomposite against Drug-Resistant Bacteria and Pathogenic Fungi

The need for smart bimetallic nanoparticles in the battle against pathogenic multi-drug resistant bacteria: a brief communication

Contact Info

Product

Resources

About